What are Ubidecarenone tablets 10 mg for heart failure?
Ubidecarenone, commonly known as Coenzyme Q10 or simply CoQ10, has garnered attention in recent years for its potential benefits in managing congestive heart failure symptoms. It is often used as a complementary therapy to alleviate symptoms and improve the overall quality of life of patients.
The mechanism of action of Ubidecarenone tablets is centered around its role in the mitochondrial electron transport chain. Ubidecarenone is a crucial cofactor in this process, facilitating the production of adenosine triphosphate, which is the primary energy source for cardiac muscle cells. In congestive heart failure, the heart's ability to pump blood efficiently is compromised, leading to fatigue and shortness of breath. Ubidecarenone helps enhance cellular energy production, enabling the heart to function more effectively.
Several clinical studies have explored the use of Ubidecarenone in CHF management. A randomized controlled trial published in the Journal of the American College of Cardiology in 2013 examined 420 CHF patients. It reported that Ubidecarenone, when added to standard therapy, significantly improved symptoms such as reduced hospitalizations and improved functional capacity. Another study published in the European Heart Journal in 2006 demonstrated that Ubidecarenone could enhance left ventricular ejection fraction (a key indicator of heart function) and decrease symptom severity in CHF patients.
Active principles: ubidecarenone
Amount: 100 tablets
Maker: Sawai Pharmaceutical Co., Ltd., Osaka, Japan
Indications: treatment of mild to moderate congestive heart failure symptoms during basic treatments
How to take
Adults should take 1 tablet 3 times a day, after meals.
Contraindications: do not use for pregnant or breastfeeding women.
Important information
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.